drugset / Trial / NCT04512534
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
Timeline
- Start
- 2020-11-13
- Primary completion
- 2026-12-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |